ProPhase Labs Engages CORE IR for Investor Relations, Public Relations and Shareholder Communications Services
01 July 2021 - 10:30PM
ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase” or the “Company”), a
diversified medical science and technology company, announced today
that it has retained CORE IR, a leading investor relations, public
relations and strategic advisory firm, to assist the Company with
investor relations, public relations and shareholder communications
services.
CORE IR will focus on expanding market awareness
for ProPhase and conveying the Company's business model and growth
strategies to the institutional and retail investment communities.
CORE IR, a boutique investor and public relations and strategic
advisory firm, specializes in leveraging the most effective
investment, growth and exposure strategies for small to mid-sized
publicly traded and privately-held companies through an integrated
approach to relationship development and corporate
communications.
“We believe CORE IR’s integrated approach to
communications will help ProPhase to expand our breadth of both
institutional and retail investors while clearly communicating our
story to the public at large.” said Ted Karkus, ProPhase’s Chief
Executive Officer. “We have a unique story that we feel will
continue to be well received as we continue on our diversification
strategy and growth trajectory.”
“CORE IR is a great fit for ProPhase and we are
very pleased to have the opportunity to work with management in
executing our integrated approach to help the Company expand their
outreach and exposure strategies. We look forward to raising market
awareness and engagement with the investment communities and to
assisting the company in achieving its goals,” added Scott Gordon,
president of CORE IR.
About CORE IR
Headquartered in Garden City, New York, CORE IR
is comprised of senior market and practice leaders with expertise
in Institutional and Retail investor relations and integrated
corporate communications and capital markets advisory services.
CORE IR provides proprietary integrated Investor and Public
Relations Solutions that yield targeted exposure for small to
mid-sized companies. For more information, please visit
www.coreir.com.About ProPhase
Labs
ProPhase Labs (Nasdaq: PRPH) (“ProPhase”) is a
diversified medical science and technology company. The Company’s
subsidiary, ProPhase Diagnostics, offers a broad array of clinical
diagnostic insights and testing services at its CLIA certified
laboratories. ProPhase Diagnostics serves patients with SARS-CoV-2
(COVID-19) through both saliva and nasal swab methods. Our
methodology also has the capability to identify the possibility of
mutations. Critical to COVID testing, results are provided in under
24 hours. ProPhase also offers PCR (polymerase chain reaction)
testing for Influenzas A and B and RSV. ProPhase Diagnostics now
offers antigen and antibody/immunity tests in partnership with
scientists to broaden its COVID-19 testing beyond RT-PCR testing.
ProPhase Labs researches, develops, manufactures, distributes,
markets, and sells OTC consumer healthcare products and dietary
supplements, including dietary supplements under the TK
Supplements® brand. ProPhase actively pursues strategic
investments and acquisition opportunities for other companies,
technologies, and products. For more information,
visit www.ProPhaseLabs.com.
Forward Looking Statements
Except for the historical information contained
herein, this document contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements regarding our ability to expand market
awareness, successfully convey our business model and growth
strategies, and expand our investor base. Management believes that
these forward-looking statements are reasonable as and when made.
However, such forward-looking statements involve known and unknown
risks, uncertainties, and other factors that may cause actual
results to differ materially from those projected in the
forward-looking statements. These risks and uncertainties include
but are not limited to the scale, scope and duration of the
COVID-19 pandemic, consumer demand for our lab processing services,
the competitive environment, challenges relating to entering into
new business lines, the failure to obtain and maintain certain
regulatory approvals, our ability to continue to ramp up our labs’
testing capacity and execute on our business plan, and the risk
factors listed from time to time in our Annual Reports on Form
10-K, Quarterly Reports on Form 10-Q and any other SEC filings.
Contact:CORE IRJules
Abraham917-885-7378julesa@coreir.com
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Apr 2024 to May 2024
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From May 2023 to May 2024